Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Shares Outstanding (2016 - 2025)

Neurocrine Biosciences' Shares Outstanding history spans 16 years, with the latest figure at $100.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 0.7% year-over-year to $100.1 million; the TTM value through Dec 2025 reached $100.1 million, up 0.7%, while the annual FY2025 figure was $100.1 million, 0.7% up from the prior year.
  • Shares Outstanding reached $100.1 million in Q4 2025 per NBIX's latest filing, roughly flat from $99.7 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $101.2 million in Q3 2024 to a low of $94.5 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $97.7 million, with a median of $97.9 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: rose 3.38% in 2024, then decreased 1.88% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $94.9 million in 2021, then increased by 1.69% to $96.5 million in 2022, then grew by 2.28% to $98.7 million in 2023, then increased by 0.71% to $99.4 million in 2024, then grew by 0.7% to $100.1 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Shares Outstanding are $100.1 million (Q4 2025), $99.7 million (Q3 2025), and $99.0 million (Q2 2025).